Corvus Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Corvus Pharmaceuticals, Inc. (CRVS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.61M, a 107.72% increase year-over-year.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.65M, a 111.83% increase year-over-year.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.25M, a 70.40% increase year-over-year.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.26M, a 63.54% increase year-over-year.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $5.33M, a 77.49% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.00M, a 39.87% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.15M, a 20.25% decline from fiscal 2022.
- Corvus Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.69M, a 36.39% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.61M 10-Q · filed 2026-08-06 | $5.26M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.65M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $5.33M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $1.25M 10-Q · filed 2025-11-04 | $2.50M derived: sum of 2 quarters · filed 2026-08-06 | $3.76M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.26M 10-Q · filed 2026-08-06 | $2.51M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.25M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $3.00M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $733.00K 10-Q · filed 2025-11-04 | $1.50M derived: sum of 2 quarters · filed 2025-11-04 | $2.19M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $768.00K 10-Q · filed 2025-11-04 | $1.46M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $689.00K 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $2.15M 10-K · filed 2026-03-12 | |||
| 2023-09-30 | $546.00K 10-Q · filed 2024-11-12 | $1.08M derived: sum of 2 quarters · filed 2024-11-12 | $1.57M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $537.00K 10-Q · filed 2024-11-12 | $1.03M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $492.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $2.69M 10-K · filed 2025-03-25 | |||
| 2022-09-30 | $658.00K 10-Q · filed 2023-11-07 | $1.33M derived: sum of 2 quarters · filed 2023-11-07 | $2.07M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $675.00K 10-Q · filed 2023-11-07 | $1.41M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $739.00K 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $4.23M 10-K · filed 2024-03-19 | |||
| 2021-09-30 | $1.10M 10-Q · filed 2022-11-03 | $2.27M derived: sum of 2 quarters · filed 2022-11-03 | $3.49M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $1.17M 10-Q · filed 2022-11-03 | $2.40M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $1.23M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $5.75M 10-K · filed 2023-03-28 | |||
| 2020-09-30 | $1.28M 10-Q · filed 2021-11-01 | $2.67M derived: sum of 2 quarters · filed 2021-11-01 | $4.51M derived: sum of 3 quarters · filed 2021-11-01 | |
| 2020-06-30 | $1.38M 10-Q · filed 2021-11-01 | $3.23M derived: sum of 2 quarters · filed 2021-11-01 | ||
| 2020-03-31 | $1.84M 10-Q · filed 2021-11-01 | |||
| 2019-12-31 | $7.35M 10-K · filed 2022-03-10 | |||
| 2019-09-30 | $1.75M 10-Q · filed 2020-10-29 | $3.65M derived: sum of 2 quarters · filed 2020-10-29 | $5.60M derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-06-30 | $1.90M 10-Q · filed 2020-10-29 | $3.85M derived: sum of 2 quarters · filed 2020-10-29 | ||
| 2019-03-31 | $1.95M 10-Q · filed 2020-10-29 | |||
| 2018-12-31 | $7.13M 10-K · filed 2021-03-25 | |||
| 2018-09-30 | $1.79M 10-Q · filed 2019-10-29 | $3.53M derived: sum of 2 quarters · filed 2019-10-29 | $5.33M derived: sum of 3 quarters · filed 2019-10-29 | |
| 2018-06-30 | $1.74M 10-Q · filed 2019-10-29 | $3.54M derived: sum of 2 quarters · filed 2019-10-29 | ||
| 2018-03-31 | $1.80M 10-Q · filed 2019-10-29 | |||
| 2017-12-31 | $6.23M 10-K · filed 2020-03-09 | |||
| 2016-12-31 | $3.83M 10-K · filed 2019-03-07 | |||
| 2015-12-31 | $428.00K 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |